NVTA
Invitae Corporation [NVTA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NVTA Stock Summary
In the News
NVTA Financial details
Company Rating
-
Market Cap
5.44M
Income
-1.44B
Revenue
481.58M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1.7K
Optionable
No
Shortable
Yes
Earnings
26 Feb 2024
P/E
-0.11
Forward P/E
-
PEG
-0.01
P/S
0.34
P/B
-0.14
P/C
-
P/FCF
-0.65
Quick Ratio
2.13
Current Ratio
2.39
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.38
EPS next Y
-
EPS next Q
-
EPS this Y
632.22%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
46.7%
Revenue last 5Y
28.44%
Revenue Q/Q
0.59%
EPS Q/Q
338.46%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-269%
ROE
473%
ROC
-3.88%
Gross Margin
27%
Oper. Margin
-303%
Profit Margin
-299%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.015-2.34
52W High
-
52W Low
-
RSI
-
Rel Volume
1.77
Avg Volume
12.7M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
1.589
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Volume Average 12.7M
- Market Capitalization 5.44M
- Employee 1.7K
- CEO Mr. Kenneth D. Knight
- Headquarters San Francisco,CA,US
- IPO Date 2015-02-12
-
Website
https://www.invitae.com 
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
